Merck's deal for Terns sparks debate over a possible biotech bidding war [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck & Co.'s $6.7 billion bid for Terns Pharmaceuticals took Wall Street by surprise, both because of its timing and the lower-than-anticipated price being paid for a much-heralded treatment that could reshape treatment of chronic myeloid leukemia. Terns' drug, called TERN-701, is a type of targeted, oral treatment that's shown early potential to challenge marketed therapies, like Novartis' Scemblix, in the treatment of CML. Yet Wall Street analysts have forecast peak annual sales estimates that effectively surpass the net $5.7 billion Merck is paying, when accounting for Terns' cash reserves. The 6% purchase premium, among the lowest paid for a publicly traded drugmaker since at least 2018, according to BioPharma Dive data , also added to a sense by some analysts and investors that rival companies may swoop in and top Merck's offer. Moreover, investors dissatisfied with the deal terms could refuse to tender their shares because they view the Merck offer as undervaluing the co
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Jim Cramer on Merck & Co.: “If We're Really Going Into an Oil Shock-Induced Slowdown, I Think This One's Likely an Outperformer”” [Yahoo! Finance]Yahoo! Finance
- Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition [Yahoo! Finance]Yahoo! Finance
- Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx [Yahoo! Finance]Yahoo! Finance
- RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium” [Yahoo! Finance]Yahoo! Finance
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline [MSNBC.com]MSNBC.com
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- MRK's page on the SEC website